SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas

Activating MYD88 mutations promote pro-survival signaling through BTK and HCK, both targets of ibrutinib. Despite high response rates, complete responses to ibrutinib are lacking, and other MYD88 triggered pro-survival pathways may contribute to primary drug resistance. B-cell receptor (BCR) signali...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood Cancer J
Asıl Yazarlar: Munshi, Manit, Liu, Xia, Chen, Jiaji G., Xu, Lian, Tsakmaklis, Nickolas, Demos, Maria G., Kofides, Amanda, Guerrera, Maria Luisa, Jimenez, Cristina, Chan, Gloria G., Hunter, Zachary R., Palomba, M. Lia, Argyropoulos, Kimon V., Meid, Kirsten, Keezer, Andrew, Gustine, Joshua, Dubeau, Toni, Castillo, Jorge J., Patterson, Christopher J., Wang, Jinhua, Buhrlage, Sara J., Gray, Nathanael S., Treon, Steven P., Yang, Guang
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Nature Publishing Group UK 2020
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC6994488/
https://ncbi.nlm.nih.gov/pubmed/32005797
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0277-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller